Blood Malignancies and Treatment

Biography

Biography: Mehrdad Payandeh

Abstract

Combination of rituximab to Cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the most effective front-line therapies to treat B-cell non-Hodgkin's lymphoma (NHL). The aim of this trial is to evaluate survival and toxicity of R-CHOP-14 compared to R-CHOP-21 in untreated stage III and IV B-cell NHL patients with Iranian ethnicity. In phase ІІІ trail, patients with previously untreated stage III and IV indolent and aggressive B-cell NHL were randomly assigned by using a minimization method to receive six cycles of either R-CHOP-21(arm A) or R-CHOP-14 (arm B). 143 patients were randomly enrolled in our study (66 patients in R-CHOP-14 group and 77 patients in R-CHOP-21). The mean follow-up was 45 months at the time of treatment analysis. 2-year and 5-year PFS rates for R-CHOP-14 group were 83.6% vs. 73.6% and for R-CHOP-21 group were 75% vs. 54%. The 2-year and 5-year OS rate for R-CHOP-14 group were 98% vs. 89% and for R-CHOP-21 group were 84.4% vs. 67.5%. There was significant correlation for PFS and OS in two arms (P<0.05), except for 2-year OS. Percentage of adverse events almost were similar in two arms and therefore there was no significant different between adverse events in two regiments. In our research that why survival improved with CHOP-14, like German group is still unknown, but it is probably drugs metabolism and its effects in different races/ethnicities are important factors. Also, adverse events in two our arms were very lower than other studies.